PMID- 28272703
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20170727
LR  - 20180322
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 21
IP  - 4
DP  - 2017 Feb
TI  - The study of endogenous hepatocyte growth factor in the pathogenesis of 
      intracranial aneurysms.
PG  - 795-803
LID - 12244 [pii]
AB  - OBJECTIVE: Inflammation as a significant influence factor plays an important role 
      in the formation and rupture of intracranial aneurysms. However, based on plenty 
      of related studies, it is believed that the hepatocyte growth factor (HGF) is 
      able to prevent vascular inflammation. This paper, therefore, explored the role 
      and mechanism of endogenous HGF in the pathogenesis of intracranial aneurysms. 
      MATERIALS AND METHODS: 16 blood samples were collected from the intracranial 
      aneurysms and the lumens of the femoral artery of 16 patients. Comparison and 
      quantitative detection of HGF serum concentrations in an aneurysm and femoral 
      artery samples according to the immune assay based on Luminex were followed. The 
      tissue of superficial temporal artery (STA) and ruptured or unruptured 
      intracranial aneurysm from the patients (n=10) who were performed surgical 
      clipping of craniotomy was then collected. The intracranial aneurysm model was 
      induced by surgery on adult c57/B16 mouse and grouping administration of c-Met 
      antagonist PF-04217903 or its solvent DMSO for 3 weeks. Then, the brains of the 
      experimental mouse were dissected and examined whether there were intracranial 
      aneurysms and/or subarachnoid hemorrhage (SAH). The procedures followed by 
      treatment of human endothelial cells cultured in vitro, smooth muscle cells and 
      monocytes with HGF and PF-04217903 lipopolysaccharide (LPS). Through Real-time 
      fluorescence quantitative PCR, with DeltaDeltaCt methods, we used the expressions of 
      beta-actin normalized inflammatory factor [intercellular adhesion molecule-1 
      (ICAM-1)], vascular cell adhesion molecule-1 (VCAM-1), E-selectin, tumor necrosis 
      factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), monocyte chemoattractant protein-1 
      (MCP-1), cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2) and transforming 
      growth factor-beta (TGF-beta). RESULTS: It was found that the concentration of HGF 
      (1076+/-656) pg/ml from the blood collected from human intracranial aneurysms was 
      significantly higher than that from the femoral artery (196+/-436) pg/ml (p<0.01). 
      Experimental mouse treated with PF-04217903 (c-Met antagonist) and in control 
      group were induced to form intracranial aneurysms. C-Met antagonists did not 
      alter the formation of intracranial aneurysms (p>0.05), but significantly 
      increased the occurrence of subarachnoid hemorrhage and reduced the survival rate 
      of mice (p<0.05). HGF attenuated the expression of VCAM-1 (p<0.05) and E-selectin 
      (p<0.05) in human aortic endothelial cells CONCLUSIONS: The plasma HGF levels 
      were elevated in intracranial aneurysms, and the HGF and c-Met were expressed in 
      STA and intracranial aneurysms. In the treatment of intracranial aneurysms, HGF 
      signaling pathway reduced inflammation in endothelial cells and prevented the 
      rupture of intracranial aneurysm through c-Met.
FAU - Yu, L-L
AU  - Yu LL
AD  - Department of Neurosurgery, Qingdao Hiser Medical Center, Qingdao, Shandong, 
      China. jbaad410@sina.com.
FAU - Liu, Y-J
AU  - Liu YJ
FAU - Wang, Z-H
AU  - Wang ZH
FAU - Shi, L
AU  - Shi L
FAU - Liu, L-X
AU  - Liu LX
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RIN - Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1176. PMID: 28387918
EDAT- 2017/03/09 06:00
MHDA- 2017/03/09 06:01
CRDT- 2017/03/09 06:00
PHST- 2017/03/09 06:00 [entrez]
PHST- 2017/03/09 06:00 [pubmed]
PHST- 2017/03/09 06:01 [medline]
AID - 12244 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2017 Feb;21(4):795-803.